Cardiol Therapeutics (TSE:CRDL) Reaches New 52-Week High – What’s Next?

Cardiol Therapeutics Inc. (TSE:CRDL) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$2.79 and last traded at C$2.78, with a volume of 169562 shares traded. The stock had previously closed at C$2.58.

Cardiol Therapeutics Trading Up 6.6%

The firm has a market cap of C$321.26 million, a P/E ratio of -8.09 and a beta of 0.27. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 5.55. The firm has a fifty day moving average of C$1.80 and a 200-day moving average of C$1.70.

Cardiol Therapeutics (TSE:CRDL) last posted its earnings results on Wednesday, August 12th. The company reported C($0.05) EPS for the quarter. Equities research analysts forecast that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.